PerkinElmer’s Sirion to develop new generation AAV vectors for diabetes gene therapy 21-Feb-2022 By Rachel Arthur PerkinElmer’s Sirion Biotech business is teaming up with the Centre for Genomic Regulation (CGR) to jointly develop new generation adeno-associated virus (AAV) vectors for type 1 and type 2 diabetes gene therapy in the pancreas.
PerkinElmer to acquire antibody and reagent company BioLegend for $5bn 26-Jul-2021 By Rachel Arthur PerkinElmer will make the largest transaction in its history with the acquisition of California’s BioLegend for $5.25bn.
PerkinElmer to acquire Horizon Discovery for $383m 02-Nov-2020 By Rachel Arthur PerkinElmer will acquire UK cell engineering company Horizon Discovery, expanding its portfolio with gene editing and gene modulation tools.
